Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes.
ABclonal has a comprehensive prokaryotic and eukaryotic protein expression system, advanced mouse monoclonal antibody production system and a fourth-generation rabbit monoclonal antibody technology. Our advanced technology allows the development of in vitro diagnostic products and customized IVD materials used in the early research and development of raw materials development services. Our clients span across the globe, including internationally renowned corporations, such as Novartis, Genetek, BGI Genomics, Novogene, 3DMed, and Maxim.
#Biotechnology #LifeScience #Antibody #ResearchTools
ABclonal has a comprehensive prokaryotic and eukaryotic protein expression system, advanced mouse monoclonal antibody production system and a fourth-generation rabbit monoclonal antibody technology. Our advanced technology allows the development of in vitro diagnostic products and customized IVD materials used in the early research and development of raw materials development services. Our clients span across the globe, including internationally renowned corporations, such as Novartis, Genetek, BGI Genomics, Novogene, 3DMed, and Maxim.
#Biotechnology #LifeScience #Antibody #ResearchTools
Location: United States, Massachusetts, Wilmington
Employees: 201-500
Phone: +1 888-754-5670
Total raised: $93M
Founded date: 2011
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.02.2021 | Series C | $93M | - |
Mentions in press and media 20
| Date | Title | Description |
| 10.01.2025 | Biotech creator and China's Keymed launch antibody company with $180M series A | U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting antibody. The new company, called Timberlyne ... |
| 09.05.2024 | Antibody Startup Emerges from Stealth: Cell Surface Bio Set to Transform the $10B Antibody Reagent Market | Company debuts catalog of validated, recombinant, specific antibodies against difficult protein targets, providing only the highest quality reagents for life sciences research PHILADELPHIA, May 9, 2024 /PRNewswire/ -- Emerging from stealth ... |
| 01.05.2023 | Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody | - |
| 15.06.2022 | YCharOS adds Developmental Studies Hybridoma Bank (DSHB) to Industry Advisory Committee | YCharOS continues to expand Industry Advisory Committee and releases new open data Adding an academic partner shows the strength and flexibility of YCharOS’ open science framework.” — Dr. Aled EdwardsTORONTO, CANADA, June 15, 2022 /EINPress... |
| 21.03.2022 | ABclonal Technology Joins YCharOS Industry Advisory Committee to Tackle Reproducibility Crisis in Biomedical Research | BOSTON, March 21, 2022 /PRNewswire/ -- ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry Advisory Committee (IAC) at YCharOS Inc., an open science c... |
| 21.03.2022 | YCharOS adds ABclonal Technology to Industry Advisory Committee | YCharOS continues to expand Industry Advisory Committee and releases new open data TORONTO, CANADA, March 21, 2022 /EINPresswire.com/ -- YCharOS Inc., an open science company with the mission of characterizing commercially available antibod... |
| 30.06.2021 | XBiotech Announces Receipt of $75 Million from Sale of Antibody | AUSTIN, Texas, June 30, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab. The True Human™ antibody developed by the company to treat... |
| 22.02.2021 | ABclonal Biotechnology Closes $93M Series C | ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing. The round was led by Sequoia Capital China and LYFE Capital, with participation from Sigma Square Capita... |
| 22.02.2021 | ABclonal Biotechnology Raises $93 Million Series C | ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholder... |
| 22.02.2021 | ABclonal Biotechnology Closes $93M Series C Financing | ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing. The round was led by Sequoia Capital China and LYFE Capital, with participation from Sigma Square Capita... |
Show more